Ruxolitinib

Ruxolitinib discontinuation syndrome and lack of efficacy: 3 case reports

    Reactions Weekly volume 1843, page322(2021)Cite this article

    This is a preview of subscription content, access via your institution.

    Access options

    Buy single article

    Instant access to the full article PDF.

    US$ 49.95

    Tax calculation will be finalised during checkout.

    Reference

    1. Palandri F, et al. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer Journal 11: 4, No. 1, Jan 2021. Available from: URL: http://doi.org/10.1038/s41408-020-00392-1

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Ruxolitinib. Reactions Weekly 1843, 322 (2021). https://doi.org/10.1007/s40278-021-91424-z

    Download citation